What does this research mean for the field?

Neoadjuvant CAPOX plus a PD-1 inhibitor achieves a 36.9% complete response rate in pMMR locally advanced rectal cancer, which is further enhanced to 61.1% with the addition of short-course radiotherapy. Novelty: ClaimNovelty.NOVEL_FINDING. Consensus alignment: ConsensusAlignment.NEUTRAL.

What question did this study set out to answer?

This trial aims to evaluate the efficacy and functional outcomes of two total neoadjuvant therapy approaches in patients with proficient mismatch repair locally advanced rectal cancer.

May 29, 2026Journal of Clinical Oncology

Immunotherapy-based total neoadjuvant therapy with or without short-course radiotherapy for locally advanced rectal cancer: Preliminary results of TORCH-iTNT.

View Full Paper

Ask AI

Bookmark

Authors

YWYaqi WangFudan University Shanghai Cancer Center LSLijun ShenFudan University Shanghai Cancer Center JWJufeng WanShanghai Medical College of Fudan University

Discussion

Member takes

Implication

Randomized trial evaluates outcomes of immunotherapy with or without radiotherapy in locally advanced rectal cancer, indicating potential benefits for treatment.

Key Points

This trial aims to evaluate the efficacy and functional outcomes of two total neoadjuvant therapy approaches in patients with proficient mismatch repair locally advanced rectal cancer.
Prospective, multicenter, randomized phase II study involving 192 patients with proficient mismatch repair locally advanced rectal cancer.
Participants were randomly assigned to either CAPOX plus PD-1 inhibitor or SCRT followed by CAPOX plus PD-1 inhibitor.
Primary endpoint was complete response rate, secondary endpoints included organ preservation and adverse effects.
Overall complete response rates were 36.9% in Group A and 61.1% in Group B.
Pathological complete response was observed in 35.2% of surgeries in Group A and 44.9% in Group B.
The most common high-grade toxicity was thrombocytopenia, with rates of 12.3% in Group A and 12.5% in Group B.

Cite This Study

Wang et al. (2026) studied this question.

synapsesocial.com/papers/6a192eb9fab5b468c4418015 https://doi.org/10.1200/jco.2026.44.16_suppl.3644

View Full Paper

Ask AI

Bookmark

Implication

Randomized trial evaluates outcomes of immunotherapy with or without radiotherapy in locally advanced rectal cancer, indicating potential benefits for treatment.

Immunotherapy-based total neoadjuvant therapy with or without short-course radiotherapy for locally advanced rectal cancer: Preliminary results of TORCH-iTNT.

Discussion

Member takes

Implication

Key Points

Cite This Study

Immunotherapy-based total neoadjuvant therapy with or without short-course radiotherapy for locally advanced rectal cancer: Preliminary results of TORCH-iTNT.

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider